Suspected leukemia oncoproteins CREB1 and LYL1 regulate Op18/STMN1 expression

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1819, Issue 11-12, 2012, Pages 1164-1172

  San Marina, Serban ^a   Han, YouQi ^a   Liu, Jian ^a   Minden, Mark D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

AML; Creb1; Creb1 Lyl1 interaction; Lyl1; Stmn1 Op18; Transcription factor

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA; LMO2 PROTEIN; LYL1 PROTEIN; NLI PROTEIN; ONCOPROTEIN; STATHMIN; STATHMIN 1; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; K562 CELLS; LEUKEMIA; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RESPONSE ELEMENTS; STATHMIN;

EID: 84867426174     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2012.09.004     Document Type: Article

References (55)

1. Ahn J., Murphy M., Kratowicz S., Wang A., Levine A.J., George D.L. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999, 18:5954-5958.
2. Alli E., Yang J.M., Ford J.M., Hait W.N. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol. Pharmacol. 2007, 71:1233-1240.
3. Alli E., Yang J.M., Hait W.N. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007, 26:1003-1012.
4. Baer R. TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin. Cancer Biol. 1993, 4:341-347.
5. Balachandran R., Welsh M.J., Day B.W. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene 2003, 22:8924-8930.
6. Belmont L., Mitchison T., Deacon H.W. Catastrophic revelations about Op18/stathmin. Trends Biochem. Sci. 1996, 21:197-198.
7. Belmont L.D., Mitchison T.J. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996, 84:623-631.
8. Benlhabib H., Herrera J.E. Expression of the Op18 gene is maintained by the CCAAT-binding transcription factor NF-Y. Gene 2006, 377:177-185.
9. Chan W.Y., Follows G.A., Lacaud G., Pimanda J.E., Landry J.R., Kinston S., Knezevic K., Piltz S., Donaldson I.J., Gambardella L., Sablitzky F., Green A.R., Kouskoff V., Gottgens B. The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype. Blood 2007, 109:1908-1916.
10. Cheng J.C., Kinjo K., Judelson D.R., Chang J., Wu W.S., Schmid I., Shankar D.B., Kasahara N., Stripecke R., Bhatia R., Landaw E.M., Sakamoto K.M. CREB is a critical regulator of normal hematopoiesis and leukemogenesis. Blood 2008, 111:1182-1192.
11. Conkright M.D., Montminy M. CREB: the unindicted cancer co-conspirator. Trends Cell Biol. 2005, 15:457-459.
12. Ferrando A.A., Neuberg D.S., Staunton J., Loh M.L., Huard C., Raimondi S.C., Behm F.G., Pui C.H., Downing J.R., Gilliland D.G., Lander E.S., Golub T.R., Look A.T. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1:75-87.
13. Ferrari A.C., Seuanez H.N., Hanash S.M., Atweh G.F. A gene that encodes for a leukemia-associated phosphoprotein (p18) maps to chromosome bands 1p35-36.1, genes chromosomes. Cancer 1990, 2:125-129.
14. Figueroa M.E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P.J., Schifano E., Booth J., van P.W., Skrabanek L., Campagne F., Mazumdar M., Greally J.M., Valk P.J., Lowenberg B., Delwel R., Melnick A. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
15. Figueroa M.E., Skrabanek L., Li Y., Jiemjit A., Fandy T.E., Paietta E., Fernandez H., Tallman M.S., Greally J.M., Carraway H., Licht J.D., Gore S.D., Melnick A. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114:3448-3458.
16. Gadea B.B., Ruderman J.V. Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/stathmin. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4493-4498.
17. Hailat N., Strahler J., Melhem R., Zhu X.X., Brodeur G., Seeger R.C., Reynolds C.P., Hanash S. N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). Oncogene 1990, 5:1615-1618.
18. Heisler L.E., Torti D., Boutros P.C., Watson J., Chan C., Winegarden N., Takahashi M., Yau P., Huang T.H., Farnham P.J., Jurisica I., Woodgett J.R., Bremner R., Penn L.Z., Der S.D. CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res. 2005, 33:2952-2961.
19. Herrero J., Valencia A., Dopazo J. A hierarchical unsupervised growing neural network for clustering gene expression patterns. Bioinformatics 2001, 17:126-136.
20. Honnappa S., Jahnke W., Seelig J., Steinmetz M.O. Control of intrinsically disordered stathmin by multisite phosphorylation. J. Biol. Chem. 2006, 281:16078-16083.
21. Hsieh S.Y., Huang S.F., Yu M.C., Yeh T.S., Chen T.C., Lin Y.J., Chang C.J., Sung C.M., Lee Y.L., Hsu C.Y. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol. Carcinog. 2010, 49:476-487.
22. Iancu C., Mistry S.J., Arkin S., Wallenstein S., Atweh G.F. Effects of stathmin inhibition on the mitotic spindle. J. Cell Sci. 2001, 114:909-916.
23. Iancu-Rubin C., Gajzer D., Tripodi J., Najfeld V., Gordon R.E., Hoffman R., Atweh G.F. Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. Blood 2011, 117:4580-4589.
24. Jean D., Bar-Eli M. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol. Cell. Biochem. 2000, 212:19-28.
25. Larsson N., Segerman B., Gradin H.M., Wandzioch E., Cassimeris L., Gullberg M. Mutations of oncoprotein 18/stathmin identify tubulin-directed regulatory activities distinct from tubulin association. Mol. Cell. Biol. 1999, 19:2242-2250.
26. Lecuyer E., Herblot S., Saint-Denis M., Martin R., Begley C.G., Porcher C., Orkin S.H., Hoang T. The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. Blood 2002, 100:2430-2440.
27. Marinescu V.D., Kohane I.S., Riva A. The MAPPER database: a multi-genome catalog of putative transcription factor binding sites. Nucleic Acids Res. 2005, 33:D91-D97.
28. Mazzoni E.O., Mahony S., Iacovino M., Morrison C.A., Mountoufaris G., Closser M., Whyte W.A., Young R.A., Kyba M., Gifford D.K., Wichterle H. Embryonic stem cell-based mapping of developmental transcriptional programs. Nat. Methods 2011, 8:1056-1058.
29. Melhem R.F., Strahler J.R., Hailat N., Zhu X.X., Hanash S.M. Involvement of OP18 in cell proliferation. Biochem. Biophys. Res. Commun. 1991, 179:1649-1655.
30. Melhem R.F., Zhu X.X., Hailat N., Strahler J.R., Hanash S.M. Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J. Biol. Chem. 1991, 266:17747-17753.
31. Mistry S.J., Bank A., Atweh G.F. Targeting stathmin in prostate cancer. Mol. Cancer Ther. 2005, 4:1821-1829.
32. Miyamoto A., Cui X., Naumovski L., Cleary M.L. Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells. Mol. Cell. Biol. 1996, 16:2394-2401.
33. Murphy M., Ahn J., Walker K.K., Hoffman W.H., Evans R.M., Levine A.J., George D.L. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 1999, 13:2490-2501.
34. Ng D.C., Lin B.H., Lim C.P., Huang G., Zhang T., Poli V., Cao X. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J. Cell Biol. 2006, 172:245-257.
35. Ogino S., Nosho K., Baba Y., Kure S., Shima K., Irahara N., Toyoda S., Chen L., Kirkner G.J., Wolpin B.M., Chan A.T., Giovannucci E.L., Fuchs C.S. A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am. J. Gastroenterol. 2009, 104:2047-2056.
36. Park S.T., Nolan G.P., Sun X.H. Growth inhibition and apoptosis due to restoration of E2A activity in T cell acute lymphoblastic leukemia cells. J. Exp. Med. 1999, 189:501-508.
37. Park S.T., Sun X.H. The Tal1 oncoprotein inhibits E47-mediated transcription. Mechanism of inhibition. J. Biol. Chem. 1998, 273:7030-7037.
38. Pavlidis P., Noble W.S. Analysis of strain and regional variation in gene expression in mouse brain. Genome Biol. 2001, 2. (p.RESEARCH0042).
39. Pirot N., Deleuze V., El-Hajj R., Dohet C., Sablitzky F., Couttet P., Mathieu D., Pinet V. LYL1 activity is required for the maturation of newly formed blood vessels in adulthood. Blood 2010, 115:5270-5279.
40. Polzin R.G., Benlhabib H., Trepel J., Herrera J.E. E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M. Gene 2004, 341:209-218.
41. Rana S., Maples P.B., Senzer N., Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev. Anticancer Ther. 2008, 8:1461-1470.
42. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., Barrette T.R., Anstet M.J., Kincead-Beal C., Kulkarni P., Varambally S., Ghosh D., Chinnaiyan A.M. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180.
43. Saeed A.I., Sharov V., White J., Li J., Liang W., Bhagabati N., Braisted J., Klapa M., Currier T., Thiagarajan M., Sturn A., Snuffin M., Rezantsev A., Popov D., Ryltsov A., Kostukovich E., Borisovsky I., Liu Z., Vinsavich A., Trush V., Quackenbush J. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:374-378.
44. San-Marina S., Han Y., Suarez S.F., Trus M.R., Minden M.D. Lyl1 interacts with CREB1 and alters expression of CREB1 target genes. Biochim. Biophys. Acta 2008, 1783:503-517.
45. Sandoval S., Pigazzi M., Sakamoto K.M. CREB: a key regulator of normal and neoplastic hematopoiesis. Adv. Hematol. 2009, 2009:634292.
46. Shankar D.B., Cheng J.C., Kinjo K., Federman N., Moore T.B., Gill A., Rao N.P., Landaw E.M., Sakamoto K.M. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 2005, 7:351-362.
47. Singer S., Ehemann V., Brauckhoff A., Keith M., Vreden S., Schirmacher P., Breuhahn K. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 2007, 46:759-768.
48. Singer S., Malz M., Herpel E., Warth A., Bissinger M., Keith M., Muley T., Meister M., Hoffmann H., Penzel R., Gdynia G., Ehemann V., Schnabel P.A., Kuner R., Huber P., Schirmacher P., Breuhahn K. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res. 2009, 69:2234-2243.
49. Souroullas G.P., Goodell M.A. A new allele of Lyl1 confirms its important role in hematopoietic stem cell function. Genesis 2011, 49:441-448.
50. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani, Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Lowenberg B., Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 2004, 350:1617-1628.
51. Wadman I.A., Osada H., Grutz G.G., Agulnick A.D., Westphal H., Forster A., Rabbitts T.H. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 1997, 16:3145-3157.
52. Wilson N.K., Foster S.D., Wang X., Knezevic K., Schutte J., Kaimakis P., Chilarska P.M., Kinston S., Ouwehand W.H., Dzierzak E., Pimanda J.E., de Bruijn M.F., Gottgens B. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 2010, 7:532-544.
53. Xing L., Gopal V.K., Quinn P.G. cAMP response element-binding protein (CREB) interacts with transcription factors IIB and IID. J. Biol. Chem. 1995, 270:17488-17493.
54. Xu Z., Huang S., Chang L.S., Agulnick A.D., Brandt S.J. Identification of a TAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentiation. Mol. Cell. Biol. 2003, 23:7585-7599.
55. Zhong Y., Jiang L., Hiai H., Toyokuni S., Yamada Y. Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice. Oncogene 2007, 26:6937-6947.